Top

Published in:

Open Access 01-12-2021 | Gastric Cancer | Research

Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer

Authors: Chuang Nie, Xu Han, Rongrong Wei, Anastasiia Leonteva, Jia Hong, Xinyu Du, Jing Wang, Lin Zhu, Yashuang Zhao, Yingwei Xue, Haibo Zhou, Wenjing Tian

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Peripheral blood leukocyte (PBL) DNA methylation may serve as a surrogate marker to evaluate the susceptibility to and prognosis of gastric cancer (GC). In this study, blood-derived DNA methylation levels of two tumour-related genes, namely, ZNF331 and WIF1, and their impacts on the risk and prognosis of GC were evaluated.

Methods

In total, 398 GC cases and 397 controls were recruited for the study. Then, all cases were followed up for 5 years. ZNF331 and WIF1 promoter methylation status in PBLs was measured using a methylation-sensitive high-resolution melting method. Logistic and Cox regression models were used to analyse the correlation between gene methylation and the risk and prognosis of GC. Confounders were balanced through propensity score (PS) matching.

Results

High ZNF331 methylation significantly decreased GC risk after PS adjustment (OR = 0.580, 95% CI: 0.375–0.898, P = 0.015), which also presented in males (OR = 0.577, 95% CI: 0.343–0.970, P = 0.038). However, WIF1 methylation was not associated with GC risk. Additionally, significant combined effects between ZNF331 methylation and the intake of green vegetables and garlic were observed (OR = 0.073, 95% CI: 0.027–0.196, P < 0.001 and OR = 0.138, 95% CI: 0.080–0.238, P < 0.001, respectively). Furthermore, ZNF331 and WIF1 methylation had no impact on the prognosis of GC.

Conclusion

ZNF331 methylation in PBLs may affect GC risk in combination with the consumption of green vegetables and garlic and may act as a potential biomarker of GC.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700–13. https://doi.org/10.1158/1055-9965.EPI-13-1057.CrossRef

Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286(5439):481–6. https://doi.org/10.1126/science.286.5439.481.CrossRefPubMed

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28. https://doi.org/10.1038/nrg816.CrossRefPubMed

Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143–53. https://doi.org/10.1038/nrc1279.CrossRefPubMed

Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 2012;22(2):246–58. https://doi.org/10.1101/gr.125872.111.CrossRefPubMedPubMedCentral

Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225–9.PubMed

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459–66. https://doi.org/10.1038/s41571-018-0004-4.CrossRefPubMed

Arasaradnam RP, Commane DM, Bradburn D, Mathers JC. A review of dietary factors and its influence on DNA methylation in colorectal carcinogenesis. Epigenetics. 2008;3(4):193–8. https://doi.org/10.4161/epi.3.4.6508.CrossRefPubMed

10.

Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2007;22(2):91–103. https://doi.org/10.1093/mutage/gel068.CrossRefPubMed

11.

Herceg Z, Vaissiere T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics. 2011;6(7):804–19. https://doi.org/10.4161/epi.6.7.16262.CrossRefPubMed

12.

Rippe V, Belge G, Meiboom M, Kazmierczak B, Fusco A, Bullerdiek J. A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors. Genes Chromosomes Cancer. 1999;26(3):229–36. https://doi.org/10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J.CrossRefPubMed

13.

Witzgall R, O'Leary E, Leaf A, Onaldi D, Bonventre JV. The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc Natl Acad Sci U S A. 1994;91(10):4514–8. https://doi.org/10.1073/pnas.91.10.4514.CrossRefPubMedPubMedCentral

14.

Yu J, Liang QY, Wang J, Cheng Y, Wang S, Poon TC, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene. 2013;32(3):307–17. https://doi.org/10.1038/onc.2012.54.CrossRefPubMed

15.

Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, et al. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer. 2015;136(4):844–53. https://doi.org/10.1002/ijc.29039.CrossRefPubMed

16.

Vedeld HM, Nesbakken A, Lothe RA, Lind GE. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10(1):70. https://doi.org/10.1186/s13148-018-0503-2.CrossRefPubMedPubMedCentral

17.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, et al. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 2017;9(1):115. https://doi.org/10.1186/s13148-017-0417-4.CrossRefPubMedPubMedCentral

18.

Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999;398(6726):431–6. https://doi.org/10.1038/18899.CrossRefPubMed

19.

Poggi L, Casarosa S, Carl M. An eye on the Wnt inhibitory factor Wif1. Front Cell Dev Biol. 2018;6:167. https://doi.org/10.3389/fcell.2018.00167.CrossRefPubMedPubMedCentral

20.

Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene. 2005;24(53):7946–52. https://doi.org/10.1038/sj.onc.1208910.CrossRefPubMed

21.

Guo H, Zhou S, Tan L, Wu X, Wu Z, Ran R. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review. Oncotarget. 2017;8(2):2550–7. https://doi.org/10.18632/oncotarget.13707.CrossRefPubMed

22.

Guo Q, Wang HB, Li YH, Li HF, Li TT, Zhang WX, et al. Correlations of promoter methylation in WIF-1, RASSF1A, and CDH13 genes with the risk and prognosis of esophageal cancer. Med Sci Monit. 2016;22:2816–24. https://doi.org/10.12659/MSM.896877.CrossRefPubMedPubMedCentral

23.

Liu P, Shen JK, Hornicek FJ, Liu F, Duan Z. Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. Sci Rep. 2017;7(1):1580. https://doi.org/10.1038/s41598-017-01763-8.CrossRefPubMedPubMedCentral

24.

Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol. 2012;22(5):384–94. https://doi.org/10.2188/jea.JE20120003.CrossRefPubMedPubMedCentral

25.

Yuasa Y. Epigenetics in molecular epidemiology of cancer a new scope. Adv Genet. 2010;71:211–35. https://doi.org/10.1016/B978-0-12-380864-6.00007-9.CrossRefPubMed

26.

Dauksa A, Gulbinas A, Endzinas Z, Oldenburg J, El-Maarri O. DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer. Anticancer Res. 2014;34(10):5381–8.PubMed

27.

Yuasa Y, Nagasaki H, Oze I, Akiyama Y, Yoshida S, Shitara K, et al. Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int J Cancer. 2012;131(11):2596–603. https://doi.org/10.1002/ijc.27554.CrossRefPubMed

28.

Zhang Y, Su HJ, Pan KF, Zhang L, Ma JL, Shen L, et al. Methylation status of blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population. Cancer Epidemiol Biomark Prev. 2014;23(10):2019–26. https://doi.org/10.1158/1055-9965.EPI-13-0994.CrossRef

29.

Sun H, Zhou H, Zhang Y, Chen J, Han X, Huang D, et al. Aberrant methylation of FAT4 and SOX11 in peripheral blood leukocytes and their association with gastric cancer risk. J Cancer. 2018;9(13):2275–83. https://doi.org/10.7150/jca.24797.CrossRefPubMedPubMedCentral

30.

Shu XO, Yang G, Jin F, Liu D, Kushi L, Wen W, et al. Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women’s health study. Eur J Clin Nutr. 2004;58(1):17–23. https://doi.org/10.1038/sj.ejcn.1601738.CrossRefPubMed

31.

Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin. 2008;1(1):7. https://doi.org/10.1186/1756-8935-1-7.CrossRefPubMedPubMedCentral

32.

Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, et al. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. 2017;38(8):797–805. https://doi.org/10.1093/carcin/bgx057.CrossRefPubMedPubMedCentral

33.

Jiang S, Linghu E, Zhan Q, Han W, Guo M. Methylation of ZNF331 promotes cell invasion and migration in human esophageal cancer. Curr Protein Pept Sci. 2015;16(4):322–8. https://doi.org/10.2174/138920371604150429155255.CrossRefPubMed

34.

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. 2009;4(12):e8274. https://doi.org/10.1371/journal.pone.0008274.CrossRefPubMedPubMedCentral

35.

Chen D, Zhang XR, Zhang Y, Zhang L, Ma JL, You WC, et al. Hypomethylation of repetitive elements in blood leukocyte DNA and risk of gastric lesions in a Chinese population. Cancer Epidemiol. 2016;41:122–8. https://doi.org/10.1016/j.canep.2016.02.004.CrossRefPubMed

36.

Rusiecki JA, Al-Nabhani M, Tarantini L, Chen L, Baccarelli A, Al-Moundhri MS. Global DNA methylation and tumor suppressor gene promoter methylation and gastric cancer risk in an Omani Arab population. Epigenomics. 2011;3(4):417–29. https://doi.org/10.2217/epi.11.65.CrossRefPubMed

37.

Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi M, Sugimura T, et al. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 2004;95(1):58–64. https://doi.org/10.1111/j.1349-7006.2004.tb03171.x.CrossRefPubMed

38.

Lee BB, Lee EJ, Jung EH, Chun H-K, Chang DK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15(19):6185–91. https://doi.org/10.1158/1078-0432.CCR-09-0111.CrossRefPubMed

39.

Roperch J-P, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13(1):566. https://doi.org/10.1186/1471-2407-13-566.CrossRefPubMedPubMedCentral

40.

Liu X, Fu J, Bi H, Ge A, Xia T, Liu Y, et al. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients. BMC Cancer. 2019;19(1):1212. https://doi.org/10.1186/s12885-019-6436-0.CrossRefPubMedPubMedCentral

41.

Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3(1):17036. https://doi.org/10.1038/nrdp.2017.36.CrossRefPubMed

42.

Fang X, Wei J, He X, An P, Wang H, Jiang L, et al. Landscape of dietary factors associated with risk of gastric cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015;51(18):2820–32. https://doi.org/10.1016/j.ejca.2015.09.010.CrossRefPubMed

43.

Ghaffari HR, Yunesian M, Nabizadeh R, Nasseri S, Sadjadi A, Pourfarzi F, et al. Environmental etiology of gastric cancer in Iran: a systematic review focusing on drinking water, soil, food, radiation, and geographical conditions. Environ Sci Pollut Res Int. 2019;26(11):10487–95. https://doi.org/10.1007/s11356-019-04493-8.CrossRefPubMed

44.

Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007;10(2):75–83. https://doi.org/10.1007/s10120-007-0420-0.CrossRefPubMed

45.

Huang D, Cui L, Ahmed S, Zainab F, Wu Q, Wang X, et al. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs. Food Chem Toxicol. 2019;123:574–94. https://doi.org/10.1016/j.fct.2018.10.052.CrossRefPubMed

46.

Zhou Y, Zhuang W, Hu W, Liu GJ, Wu TX, Wu XT. Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis. Gastroenterology. 2011;141(1):80–9. https://doi.org/10.1053/j.gastro.2011.03.057.CrossRefPubMed

47.

Sparnins VL, Barany G, Wattenberg LW. Effects of organosulfur compounds from garlic and onions on benzo [a]pyrene-induced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis. 1988;9(1):131–4. https://doi.org/10.1093/carcin/9.1.131.CrossRefPubMed

48.

Xu Y, Su D, Zhu L, Zhang S, Ma S, Wu K, et al. S-allylcysteine suppresses ovarian cancer cell proliferation by DNA methylation through DNMT1. J Ovarian Res. 2018;11(1):39. https://doi.org/10.1186/s13048-018-0412-1.CrossRefPubMedPubMedCentral

49.

Jung M, Pfeifer GP. Aging and DNA methylation. BMC Biol. 2015;13(1):7. https://doi.org/10.1186/s12915-015-0118-4.CrossRefPubMedPubMedCentral

50.

Lin S, Liu Y, Goldin LR, Lyu C, Kong X, Zhang Y, et al. Sex-related DNA methylation differences in B cell chronic lymphocytic leukemia. Biol Sex Differ. 2019;10(1):2. https://doi.org/10.1186/s13293-018-0213-7.CrossRefPubMedPubMedCentral

51.

Woo HD, Fernandez-Jimenez N, Ghantous A, Degli Esposti D, Cuenin C, Cahais V, et al. Genome-wide profiling of normal gastric mucosa identifies helicobacter pylori- and cancer-associated DNA methylome changes. Int J Cancer. 2018;143(3):597–609. https://doi.org/10.1002/ijc.31381.CrossRefPubMed

52.

Muhammad JS, Eladl MA, Khoder G. Helicobacter pylori-induced DNA methylation as an epigenetic modulator of gastric cancer: recent outcomes and future direction. Pathogens. 2019;8(1):23. https://doi.org/10.3390/pathogens8010023.CrossRefPubMedCentral

53.

Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35(6):e41. https://doi.org/10.1093/nar/gkm013.CrossRefPubMedPubMedCentral

54.

Wojdacz TK, Borgbo T, Hansen LL. Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics. 2009;4(4):231–4. https://doi.org/10.4161/epi.9020.CrossRefPubMed

55.

Wong EM, Dobrovic A. Assessing gene-specific methylation using HRM-based analysis. Methods Mol Biol. 2011;687:207–17. https://doi.org/10.1007/978-1-60761-944-4_14.CrossRefPubMed

56.

Hussmann D, Hansen LL. Methylation-sensitive high resolution melting (MS-HRM). Methods Mol Biol. 2018;1708:551–71.CrossRef

57.

Liu Y, Wang Y, Hu F, Sun H, Zhang Z, Wang X, et al. Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China. Oncotarget. 2017;8(37):61239–52. https://doi.org/10.18632/oncotarget.18054.CrossRefPubMedPubMedCentral

58.

Gao HL, Wang X, Sun HR, Zhou JD, Lin SQ, Xing YH, et al. Methylation status of transcriptional modulatory genes associated with colorectal cancer in Northeast China. Gut Liver. 2018;12(2):173–82. https://doi.org/10.5009/gnl17163.CrossRefPubMedPubMedCentral

59.

Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol. 1990;132(4):746–8. https://doi.org/10.1093/oxfordjournals.aje.a115716.CrossRefPubMed

60.

Flegal KM, Brownie C, Haas JD. The effects of exposure misclassification on estimates of relative risk. Am J Epidemiol. 1986;123(4):736–51. https://doi.org/10.1093/oxfordjournals.aje.a114294.CrossRefPubMed

61.

Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105(5):488–95. https://doi.org/10.1093/oxfordjournals.aje.a112408.CrossRefPubMed

Title: Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer
Authors: Chuang Nie
Xu Han
Rongrong Wei
Anastasiia Leonteva
Jia Hong
Xinyu Du
Jing Wang
Lin Zhu
Yashuang Zhao
Yingwei Xue
Haibo Zhou
Wenjing Tian
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08199-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial

The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer